URGN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

UR

Mkt Cap

$1.69B

Volume

683.72K

Next Earnings

November 5th

Loading chart

UR

URGNUroGen Pharma Ltd. Ordinary Shares

URGN

Pay with—

Available Balance0.00

UR

Mkt Cap

$1.69B

Volume

683.72K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Here's Why You Should Add URGN Stock to Your Portfolio NowUroGen Pharma is transitioning from development-stage to commercial-growth biotech, driven by strong Zusduri uptake (73% sequential revenue growth to $50.4M in Q2 2026) and stable Jelmyto sales ($22M in Q2). The company's pipeline includes promising candidates like UGN-103 (94.5% response rate with NDA submitted) and UGN-104, with potential to expand beyond urothelial cancers through a strategic collaboration with IntraGel.Zacks Investment Research · Sep 30, 2026

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in FocusZacks highlights strong stock performance from its various rating systems and portfolios. Oportun Financial gained 31% after a Zacks Rank upgrade, Uranium Royalty advanced 67.6% following an Outperform recommendation, and Amgen returned 25.1% over 12 weeks. The article discusses economic conditions marked by geopolitical tensions, rising energy costs, and resilient but cooling labor markets, while showcasing the historical outperformance of Zacks' investment methodologies.Zacks Investment Research · Sep 8, 2026

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 19 new employees, with up to 117,100 ordinary shares issuable upon vesting over three years. The company also announced a strategic collaboration and investment agreement with IntraGel Therapeutics to access a biodegradable sustained-release gel platform and expand its uro-oncology and specialty cancer pipeline.GlobeNewswire Inc. · Sep 4, 2026

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% RunUroGen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 shares worth $400,000 on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in August 2025. Despite the sale, Schoenberg retains 119,763 shares valued at $4.82 million. The transaction should not be viewed negatively as it was scheduled long in advance and the CMO maintains significant holdings. UroGen's Zusduri bladder cancer therapy is performing well with Q1 revenue jumping 152% to $51 million, and the company recently received FDA clearance for an investigational new drug application for UGN-501.The Motley Fool · Jul 12, 2026

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 5,222 shares for approximately $143,000 on June 8, 2026, reducing his holdings by 3.60%. While his remaining stake of 139,763 shares keeps his interests aligned with investors, the sale follows a pattern of regular dispositions over the past year. The company faces headwinds from an upcoming generic competition agreement with Teva Pharmaceuticals for its flagship drug Jelmyto starting September 2030, though growth in other products like Zusduri may offset losses.The Motley Fool · Jun 14, 2026

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of RecurrenceA national survey of over 1,100 bladder cancer patients conducted by the Bladder Cancer Advocacy Network (BCAN) reveals that nearly 80% of patients report fear of recurrence, with rates exceeding 90% among those under 50. The report documents significant procedural burden, with many patients undergoing five or more cystoscopies. UroGen Pharma commended the findings, emphasizing the need for treatment approaches that consider long-term quality of life alongside tumor control.GlobeNewswire Inc. · Mar 13, 2026

Bladder Cancer Patients Report Delayed Diagnosis and Gaps in SupportA comprehensive survey of over 1,100 bladder cancer patients reveals significant gaps in care despite advances in treatment. Key findings include diagnostic delays for women (45% initially misdiagnosed with UTIs), inadequate mental health support (41% never offered resources), and financial barriers affecting treatment decisions, particularly for younger patients.GlobeNewswire Inc. · Mar 13, 2026

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% RallyWildcat Capital Management, the family office of late billionaire David Bonderman, completely exited its position in UroGen Pharma by selling 495,606 shares worth $6.79 million in Q3. Despite UroGen's impressive 113% one-year rally, the exit signals disciplined profit-taking rather than loss of confidence, as biotech winners often see valuation risk increase after strong rallies.The Motley Fool · Dec 26, 2025

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)UroGen Pharma granted restricted stock units to 14 new employees to support commercialization of Jelmyto and ZUSDURI, with up to 32,500 ordinary shares issuable upon vesting over three years.GlobeNewswire Inc. · Dec 5, 2025

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare ConferenceUroGen Pharma will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in a fireside chat format, discussing their innovative cancer treatment technologies.GlobeNewswire Inc. · Nov 25, 2025

to start trading

UR

URGNUroGen Pharma Ltd. Ordinary Shares

URGN

Pay with—

Available Balance0.00

Your PositionYou don't own any URGN yet.

Related Tickers

Earnings